Author(s)

Juan C. Manrique-Arias^1,2*, Quetzali Pitalua-Cortes¹, Roberto Pedrero-Piedras¹, Géiser Rodríguez-Mena¹, Tessy López³, Cristian Cabezas-Ortiz¹, Osvaldo García-Pérez¹

¹Departamento de Medicina Nuclear, Ciclotrón y Radiofarmacia Instituto Nacional de Cancerología, México City, México.
²Cancer Center Cyclotron Department, Doctors Hospital, Monterrey, México.
³Departamento de Atención a la Salud, Universidad Autónoma Metropolitana-Xochimilco, México City, México.

This Bombesin (BBN), a tetradecapeptide analog of human gastrin-releasing peptide (GRP) with a high binding affinity for GRP receptors (GRPR), is over- expressed in early stages of androgen-dependent prostate carcinomas, but not in advanced stages. Therefore, there is a need to develop effective tracers for the accurate and specific detection of this disease. The objective of this study was to evaluate Lys¹, Lys³-DOTA-BBN (1,14) analog with the radiolabeled positron emitter [⁶⁸Ga]-Ga-BBN for receptor imaging with PET, and to determine its biodistribution and radiation dosimetry using whole-body (WB) PET scans in healthy volunteers. The highest uptake was in the pancreas, followed by urinary bladder. The critical organ was pancreas with a mean absorbed dose of 206 ± 0.7, 210 ± 0.7, 120 ± 0.9, 390.23 ± 0.6 μGy/MBq and the effective doses were estimated as 73.2 ± 0.6, 49.8 ± 0.3 μGy/MBq (women and men, respectively).

Radiation Dosimetry, Biodistribution, PET Imaging, Radiopharmaceutical, Lys¹, Lys³-DOTA-BBN (1, 14), Bombesin Analogs

Manrique-Arias, J. , Pitalua-Cortes, Q. , Pedrero-Piedras, R. , Rodríguez-Mena, G. , López, T. , Cabezas-Ortiz, C. and García-Pérez, O. (2020) Synthesis and Radiation Dosimetry of [⁶⁸Ga]-Ga-Lys¹, Lys³-DOTA-Bombesin (1,14) Antagonist for PET-Imaging, as a Potential Theragnostic Tracer in Oncology. Journal of Encapsulation and Adsorption Sciences, 10, 29-41. doi: 10.4236/jeas.2020.102002.